Reconnecting Practicing Hygienists with the Nation's Leading Educators and Researchers.

LED Dental Inc. Wins Federal Supply Schedule Contract

British Columbia, Canada – March 14, 2007 – LED Dental Inc., a Vancouver-based medical device company, recently announced that it has been awarded Federal Supply Schedule Contract V797P-3134M by the Department of Veterans Affairs in Hines, IL. Although issued by the Department of . . .

LED Dental Inc. Wins Federal Supply Schedule Contract

Company Authorized to Sell its VELscope® Oral Mucosal Examination Device

to all U.S. Government Agencies

British Columbia, Canada – March 14, 2007 – LED Dental Inc., a Vancouver-based medical device company, recently announced that it has been awarded Federal Supply Schedule Contract V797P-3134M by the Department of Veterans Affairs in Hines, IL.

Although issued by the Department of Veterans Affairs (VA), the contract enables LED Dental to market its VELscope® (Visually Enhanced Lesion Scope) oral mucosal examination system directly to any and all U.S. Government agencies. In particular, the 5.5 million military veterans eligible for VA services represent a high-risk population for the incidence of oral cancer.

“This is a very important contract for us,” said LED Dental President and CEO Steven Semmelmayer. “Not only from a business perspective, but because we believe it’s important to provide military veterans with the best possible standard of healthcare, including the prevention and early detection of life-threatening diseases such as oral cancer.”

VELscope® is an adjunctive oral mucosal examination device that utilizes a narrow band of blue light and specialized filtering technology to help dental professionals evaluate oral mucosa for abnormal areas of concern, such as potentially cancerous lesions that may not be apparent under white light.

The Federal Supply Schedule Contract is effective through February 14, 2012. LED Dental has appointed Debra Vanier (debra.vanier@led-md.com), Institutional Sales Representative, to handle inquiries regarding institutional sales.

VELscope’s Direct Tissue Fluorescence Visualization Technology platform was developed by the British Columbia Cancer Agency (BCCA) and its U.S. partners, including MD Anderson Cancer Center, with financing provided in part by over $50 million in grants from the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, a U.S. government-funded agency.


<< Back

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy